BIO Wants More Binding FDA/Sponsor Meetings As Part Of PDUFA III
Executive Summary
The Biotechnology Industry Organization is seeking to use PDUFA reform to write a requirement into FDA's legislative mandate for more binding consultations between BLA sponsors and FDA staff before the actual application review begins
You may also be interested in...
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
FDA's working group on CBER/CDER consolidation will meet for the first time the week of Sept. 16
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
FDA's working group on CBER/CDER consolidation will meet for the first time the week of Sept. 16
CBER/CDER Merger Is One Topic Of Erbitux Discussions In House Cmte.
The House Energy & Commerce Committee investigation of the Erbitux review could re-energize proposals to combine FDA's drugs and biologics centers